利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

590 条记录 (耗时 0.048 秒)

    Cysteine engineered antibodies and conjugates
    93.
    发明申请
    Cysteine engineered antibodies and conjugates 有权
    半胱氨酸改造的抗体和缀合物

    公开(公告)号：US20070092940A1

    公开(公告)日：2007-04-26

    申请号：US11233258

    申请日：2005-09-22

    申请人： Charles Eigenbrot ,  Jagath Junutula ,  Henry Lowman ,  Helga Raab ,  Richard Vandlen

    发明人： Charles Eigenbrot ,  Jagath Junutula ,  Henry Lowman ,  Helga Raab ,  Richard Vandlen

    IPC分类号： C12P21/08 ,  C07H21/04 ,  C07K16/28 ,  C12N15/86

    CPC分类号： A61K47/6803 ,  A01K2267/0331 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/00 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/624

    摘要： Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p  I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

    摘要翻译： 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合以形成具有式I的半胱氨酸改造的抗体 - 药物共轭物： in-line-formula description =“In-line Formulas”end =“lead”？> Ab-（LD）

    I <？in-line-formula description =“In-line Formulas”end =“尾”→其中p为1至4.公开了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。

    Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
    94.
    发明申请
    Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods 审中-公开
    胰腺癌相关抗原，抗体及其诊断和治疗方法

    公开(公告)号：US20060258841A1

    公开(公告)日：2006-11-16

    申请号：US10542239

    申请日：2004-01-16

    申请人： Josef Michl ,  Stefan Bradu ,  Raquib Hannan ,  Matthew Pincus

    发明人： Josef Michl ,  Stefan Bradu ,  Raquib Hannan ,  Matthew Pincus

    IPC分类号： C07K14/82 ,  C07K16/30

    CPC分类号： C07K16/303 ,  A61K47/6817 ,  A61K47/6859 ,  A61K51/1057 ,  A61K2039/505 ,  C07K14/47 ,  C07K2317/24 ,  C07K2317/734 ,  G01N33/57438 ,  G01N2333/705

    摘要： The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

    摘要翻译： 本发明涉及在大鼠和人胰腺癌细胞表面上发现的抗原，并且提供对该抗原以及分泌本发明抗体的杂交瘤具有高特异性和选择性的抗体。 还提供了胰腺癌诊断和治疗方法。 胰腺腺癌组织标志物，一种约43.5 kD的表皮膜蛋白，称为PaCa-Ag1，在正常胰腺中完全未表达，但在胰腺癌细胞中大量表达。 此外，使用受试抗体，存在可溶形式的PaCa-Ag1，其分子量约36至约38kD，其易于在胰腺癌患者的血清和其它体液中鉴定。

    Prevention and treatment of cardiovascular pathologies
    96.
    发明申请
    Prevention and treatment of cardiovascular pathologies 审中-公开
    预防和治疗心血管病变

    公开(公告)号：US20060029986A1

    公开(公告)日：2006-02-09

    申请号：US11231256

    申请日：2005-09-20

    申请人： David Grainger ,  Paul Kemp

    发明人： David Grainger ,  Paul Kemp

    IPC分类号： G01N33/542 ,  G01N33/537

    CPC分类号： A61K9/0024 ,  A61K31/00 ,  A61K31/135 ,  A61K31/138 ,  A61K31/337 ,  A61K31/38 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/715 ,  A61K47/51 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6831 ,  A61K47/6843 ,  A61K47/6927 ,  A61K47/6937 ,  A61K47/6957 ,  C07K14/71 ,  C07K16/22 ,  C07K2317/73 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/495 ,  G01N2800/32

    摘要： A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C═O or a covalent bond; Y is H or O(C1-C4)alkyl, R1 and R2 are individually (C1-C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1-C4)alkyl or H and R6 is 1, O(C1-C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and/or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

    摘要翻译： 一种治疗或预​​防心血管病变的方法，其通过给予式（I）化合物：其中Z为C-O或共价键; Y是H或O（C 1 -C 4）烷基，R 1和R 2各自独立地是（ C 1 -C 4烷基或与N一起为饱和杂环基，R 3是乙基或氯乙基，R 4 H或与R 3一起为-CH 2 - ， - CH 2 - 或-S-，R 5 是（O）（C 1 -C 4 - ）烷基或H，且R 6是1，O（C 1个C 1 -C 4烷基或H，条件是当R 4，R 5，R 5， 6是H，R 3不是乙基; 提供有效激活或刺激TGF-β的产生以治疗和/或预防诸如动脉粥样硬化，血栓形成，心肌梗死和中风的病症的药学上可接受的盐或其药学上可接受的盐。 有用的化合物包括异昔芬及其盐。 还提供了鉴定作为TGF-β激活剂或生产刺激剂的化合物的方法。 本发明的另一个实施方案是用于在体外测定TGF-β的测定或试剂盒。 还提供了一种治疗方法，其包括使用给予他莫昔芬或其结构类似物（包括式（I）的化合物）来抑制与程序性血管创伤相关的平滑肌细胞增殖。

    Drug conjugate composition
    97.
    发明申请
    Drug conjugate composition 有权
    药物缀合物组成

    公开(公告)号：US20040241174A1

    公开(公告)日：2004-12-02

    申请号：US10846129

    申请日：2004-05-14

    申请人： ImmunoGen, Inc.

    发明人： Godfrey Amphlett ,  Wei Zhang ,  Michael Fleming ,  Hung-Wei Chih

    IPC分类号： A61K039/395 ,  C07K016/46

    CPC分类号： A61K47/48384 ,  A61K9/19 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6803 ,  A61K47/6817 ,  A61K47/6851 ,  A61K47/6857 ,  C07K16/2803 ,  C07K2317/24

    摘要： The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.

    摘要翻译： 本发明提供一种液体组合物和冻干组合物，其包含治疗有效量的包含与美登木素生物素化学偶联的抗体的缀合物。 本发明进一步提供了一种杀死人体细胞的方法，包括对人体施用组合物使得抗体结合细胞表面，并且美登木素生物碱的细胞毒性被激活，由此细胞被杀死。

    Photodynamic treatment of targeted cells
    98.
    发明申请
    Photodynamic treatment of targeted cells 有权
    光动力治疗靶细胞

    公开(公告)号：US20040215292A1

    公开(公告)日：2004-10-28

    申请号：US10802284

    申请日：2004-03-16

    发明人： James Chen

    IPC分类号： A61N001/00

    CPC分类号： A61K41/0057 ,  A61K41/0061 ,  A61K41/0071 ,  A61K47/6817 ,  A61K47/6835 ,  A61K47/6849 ,  A61K47/6867 ,  A61N5/062

    摘要： The present invention is drawn to methods for photodynamic therapy (PDT) of a target cell, target tissue or target composition in a mammalian subject, using a therapeutically effective amount of a targeted substance, which is either a targeted photosensitizing agent, or a photosensitizing agent delivery system, or a targeted prodrug. This targeted substance preferably selectively binds to the target cell, target tissue or target composition. Light at a wavelength or waveband corresponding to that which is absorbed by the targeted substance is then administered. The light intensity is relatively low, but a high total fluence is employed to ensure the activation of the targeted photosensitizing agent or targeted prodrug product.

    摘要翻译： 本发明涉及使用治疗有效量的靶向物质作为靶向细胞，靶组织或目标组合物的光动力学治疗（PDT）的方法，所述目标物质是靶向光敏剂或光敏剂 递送系统或靶向前药。 该靶向物质优选选择性地结合靶细胞，靶组织或靶组成。 然后施用对应于被靶向物质吸收的波长或波段的光。 光强度相对较低，但采用高总能量密度来确保目标光敏剂或靶向前药产品的活化。